Variant B7 co-stimulatory molecules

Details Variant B7 co-stimulatory molecules Variant B7 co-stimulatory molecules

2007-02-27

2007-02-27

Gambel, Phillip (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C530S387300, C514S012200, C424S134100

Reexamination Certificate

active

10032214

ABSTRACT:
The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.

REFERENCES:
patent: 5475099 (1995-12-01), Knauf et al.
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5718883 (1998-02-01), Harlan et al.
patent: 5738852 (1998-04-01), Robinson et al.
patent: 5858776 (1999-01-01), Ostrand-Rosenberg et al.
patent: 5861310 (1999-01-01), Freeman et al.
patent: 5942607 (1999-08-01), Freeman et al.
patent: 6045802 (2000-04-01), Schlom et al.
patent: 6071716 (2000-06-01), Freeman et al.
patent: 6084067 (2000-07-01), Freeman et al.
patent: 6130316 (2000-10-01), Freeman et al.
patent: 6149905 (2000-11-01), Ostrand-Rosenberg et al.
patent: 6653444 (2003-11-01), Freeman et al.
patent: 2003/0170821 (2003-09-01), Freeman et al.
patent: WO 94/24267 (1994-10-01), None
patent: WO 95/03408 (1995-02-01), None
patent: WO 95/23859 (1995-09-01), None
patent: WO 99/43839 (1999-09-01), None
patent: WO 99/57271 (1999-11-01), None
Parsons, K.R., et al.,Immunogenetics(1999) 49:231-234.
Peach, R.J., et al.,Journal of Biological Chemistry(1995) 270(36):21181-21187.
Fargeas, C.A., et al.,Journal of Experimental Medicine(1995) 182(3):667-675.
Faas, S.J., et al.,Journal of Immunology(2000) 164(12):6340-6348.
Chang, C-C J., et al.,Nature Biotechnology(1999) 17(8):793-797.
Crameri, A., et al.,Nature(1998) 391:288-291.
Guo, Y., et al.,Journal of Experimental Medicine(1995) 181(4):1345-1355.
Stemmer, W.P.C.,Nature(1994) 370:389-391.
Lazetic, S., et al.,Journal of Biological Chemistry(2002) 277(41):38660-38668.
He, X-S. et al., “Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen,” Proc. Natl. Acad. Sci. USA 93:7274-7278 (1996).
Kuchroo, V.K. et al., “B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy,” Cell 80:707-718 (1995).
Metzler, W., et al., “Solution Structure of Human CTLA-4 and Delineation of a CD80/CD86 Binding Site Conserved in CD28,” Nature Structural Biology 4(7):527-531 (Jul. 1997).
Rennert, P. et al., “The lgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion,” International Immunology 9(6):805-813 (1997).
Wu, Y., “CTLA-4-B7 Interaction is Sufficient to Costimulate T Cell Clonal Expansion,” J. Exp. Med. 185(7):1327-1336 (1997).
Doty, R. et al., “Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation,”Journal of Immunology157:3270-3279 (1996).
Linsley, P.S. et al., “Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors,”Immunity1:793-801 (Dec. 1994).
Linsley, P.S. et al., “Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation,”J. Exp. Med. 173:721-730 (Mar. 1991).
Sturmhoefel, K., “Potent activity of soluble B7-lgG fusion proteins in therapy of established tumors and as vaccine adjuvant,”Cancer Research59:4964-4972 (Oct. 1999).
Swiniarski, H. et al., “Immune response enhancement byin vivoadministration of B7.21g, a soluble costimulatory protein,”Clinical Immunology92(3):235-245 (1999).
Azuma, M. et al., “B70 Antigen is a Second Ligand for CTLA-4 and CD28,”Nature366:76-79 (1993).
Freeman, G.J. et al., “Cloning of B7-2: A CTLA-4 Counter-Recepetor that Costimulates Human T Cell Proliferation,”Science262:909-911 (1993).
Freeman, G.J. et al., “B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells,”J. Immunol.143:2714-22 (1989).
Isono, T. & Seto, A.,Immunogenetics42:217-20 (1995).
Kim, J.J. et al., “Engineering DNA Vaccines Via Co-delivery of Co-Stimulatory Molecule Genes,”Vaccine16(19):1828-1835 (1998).
Lazetic, S. et al., “Chimeric Co-stimulatory Molecules that Selectively Act Through CD28 or CTLA-4 on Human T Cells,”J. Biol. Chem. 277(41):38660-38668 (2002).
Parsons, K.R., et al., “Cloning of Cattle CD80,”Immunogenetics49(3):231-234 (1999).
Patten, P. et al., “Applications of DNA Shuffling to Pharmaceuticals and Vaccines,”Current Opinion in Biotechnology8:724-733 (1997).
Peach, R. et al., “Complementary Determining Region 1 (CDR1)- and CDR3-Analogous Regions in CTLA-4 and CD28 Determine the Binding to B7-1,”J. Exp. Med.180:2049-2058 (1994).
Stamper, C. et al., “Crystal Structure of the B7-1/CTLA-4 Complex that inhibits Human Immune Responses,”Nature410:608-611 (Mar. 2001).
Stemmer, W. et al., “Searching Sequence Space: Using Recombination to Search More Efficiently and Thoroughly Instead of Making Bigger Combinatorial Libraries,”Biotechnology13:549-553 (1995).

Affiliated with

Also associated with

Rating

Variant B7 co-stimulatory molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Variant B7 co-stimulatory molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variant B7 co-stimulatory molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3887288